Clinical Trial

A Study of MHB036C Combined With Anti-tumor Therapies in Patients With Advanced Lung Cancer

Recruiting Phase 1/2
View on ClinicalTrials.gov →
Summary
This is a first-in-human, open-label, multicenter Phase I/II study of MHB036C combined with MHB039A or other anti-tumor therapy in patients with advanced lung cancer. The study was designed to evaluate the safety, tolerability, pharmacokinetics (PK), and preliminary efficacy of MHB036C combined with MHB039A or other anti-tumor therapies.
Trial Details
NCT Number NCT07229599
Lead Sponsor Minghui Pharmaceutical (Hangzhou) Ltd
Conditions Advanced Lung Cancer
Enrollment 300 participants
Start Date 2025-05-09
Primary Completion 2029-05 (estimated)
Study Completion 2030-05 (estimated)
Updated on ClinicalTrials.gov 2025-11-17